Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jul;39(7):1485–1488. doi: 10.1128/aac.39.7.1485

Evaluation of retinal toxicity and efficacy of the anticytomegalovirus compound 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine.

G Besen 1, E Chavez-de la Paz 1, M Tatebayashi 1, M Flores-Aguilar 1, P A Gangan 1, D Munguia 1, C A Wiley 1, G Jähne 1, I Winkler 1, M Helsberg 1, et al.
PMCID: PMC162767  PMID: 7492090

Abstract

Compound 2242, also known as 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine, is the first known antivirally active nucleoside analog with the side chain substituted at the N-7 position of the purine ring system. Our purpose was to evaluate its retinal toxicity and assess the efficacy of its highest nontoxic concentration in a rabbit model of herpes simplex retinitis. Concentrations of the drug from 0.5 to 2,000 microM were injected intravitreally in twelve New Zealand White rabbits. Fundoscopic, histologic, and electrophysiologic data revealed no evidence of toxicity even at the highest dose of the compound. Dutch pigmented rabbits (n = 34) had their left eyes injected with herpes simplex virus type 1 3 days after, concurrently, or 3 days before intravitreal injection of either 2,000 microM compound 2242 or 480 microM ganciclovir (final concentration in the eye). Both compound 2242 and ganciclovir were equally effective compared with saline when administered simultaneously with the virus (P < 0.0001). In the 3-day pretreatment paradigm, compound 2242 was superior to ganciclovir (P < 0.04), but there was no clear difference between the two with regard to their effects on an established infection. The pharmacokinetics of compound 2242 in 10 rabbits injected intravitreally with 30 microM showed an intravitreal half-life of 8 h. This compound, which may be orally active in its pro form, has a very high therapeutic index in the eye and is more efficient than ganciclovir in this animal model of herpes retinitis.

Full Text

The Full Text of this article is available as a PDF (366.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anand R., Nightingale S. D., Fish R. H., Smith T. J., Ashton P. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol. 1993 Feb;111(2):223–227. doi: 10.1001/archopht.1993.01090020077027. [DOI] [PubMed] [Google Scholar]
  2. Cantrill H. L., Henry K., Melroe N. H., Knobloch W. H., Ramsay R. C., Balfour H. H., Jr Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results. Ophthalmology. 1989 Mar;96(3):367–374. doi: 10.1016/s0161-6420(89)32900-9. [DOI] [PubMed] [Google Scholar]
  3. Cochereau-Massin I., Lehoang P., Lautier-Frau M., Zazoun L., Marcel P., Robinet M., Matheron S., Katlama C., Gharakhanian S., Rozenbaum W. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1991 Sep;98(9):1348–1355. doi: 10.1016/s0161-6420(91)32135-3. [DOI] [PubMed] [Google Scholar]
  4. Dolnak D. R., Munguia D., Wiley C. A., De Clercq E., Bergeron-Lynn G. L., Boscher C., Connor J. D., Sherwood C., Capparelli E., Armani R. Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine. Invest Ophthalmol Vis Sci. 1992 Apr;33(5):1557–1563. [PubMed] [Google Scholar]
  5. Díaz-Llopis M., Chipont E., Sanchez S., España E., Navea A., Menezo J. L. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol. 1992 Dec 15;114(6):742–747. doi: 10.1016/s0002-9394(14)74054-1. [DOI] [PubMed] [Google Scholar]
  6. Erice A., Chou S., Biron K. K., Stanat S. C., Balfour H. H., Jr, Jordan M. C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 1989 Feb 2;320(5):289–293. doi: 10.1056/NEJM198902023200505. [DOI] [PubMed] [Google Scholar]
  7. Fanning M. M., Read S. E., Benson M., Vas S., Rachlis A., Kozousek V., Mortimer C., Harvey P., Schwartz C., Chew E. Foscarnet therapy of cytomegalovirus retinitis in AIDS. J Acquir Immune Defic Syndr. 1990;3(5):472–479. [PubMed] [Google Scholar]
  8. Flores-Aguilar M., Kuppermann B. D., Quiceno J. I., Dankner W. M., Wolf D. G., Capparelli E. V., Connor J. D., Sherwood C. H., Fullerton S., Gambertoglio J. G. Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis. Ophthalmology. 1993 Jul;100(7):1022–1031. doi: 10.1016/s0161-6420(93)31523-x. [DOI] [PubMed] [Google Scholar]
  9. Flores-Aguilar M., Munguia D., Loeb E., Crapotta J. A., Vuong C., Shakiba S., Bergeron-Lynn G., Wiley C. A., Weers J., Freeman W. R. Intraocular tolerance of perfluorooctylbromide (perflubron) Retina. 1995;15(1):3–13. [PubMed] [Google Scholar]
  10. Freeman W. R. Intraocular antiviral therapy. Arch Ophthalmol. 1989 Dec;107(12):1737–1739. doi: 10.1001/archopht.1989.01070020819020. [DOI] [PubMed] [Google Scholar]
  11. Freeman W. R., Schneiderman T. E., Wiley C. A., Listhaus A. D., Svendsen P., Munguia D., Bergeron-Lynn G. An animal model of focal, subacute, viral retinitis. Retina. 1993;13(3):214–221. doi: 10.1097/00006982-199313030-00005. [DOI] [PubMed] [Google Scholar]
  12. Heinemann M. H. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol. 1989 Dec;107(12):1767–1772. doi: 10.1001/archopht.1989.01070020849025. [DOI] [PubMed] [Google Scholar]
  13. Henderly D. E., Freeman W. R., Causey D. M., Rao N. A. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology. 1987 Apr;94(4):425–434. doi: 10.1016/s0161-6420(87)33454-2. [DOI] [PubMed] [Google Scholar]
  14. Henry K., Cantrill H., Fletcher C., Chinnock B. J., Balfour H. H., Jr Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol. 1987 Jan 15;103(1):17–23. doi: 10.1016/s0002-9394(14)74163-7. [DOI] [PubMed] [Google Scholar]
  15. Jabs D. A., Enger C., Bartlett J. G. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989 Jan;107(1):75–80. doi: 10.1001/archopht.1989.01070010077031. [DOI] [PubMed] [Google Scholar]
  16. Knox K. K., Drobyski W. R., Carrigan D. R. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet. 1991 May 25;337(8752):1292–1293. doi: 10.1016/0140-6736(91)92965-5. [DOI] [PubMed] [Google Scholar]
  17. Kuppermann B. D., Flores-Aguilar M., Quiceno J. I., Rickman L. S., Freeman W. R. Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Arch Ophthalmol. 1993 Oct;111(10):1359–1366. doi: 10.1001/archopht.1993.01090100067029. [DOI] [PubMed] [Google Scholar]
  18. Kusmierek J. T., Czochralska B., Johansson N. G., Shugar D. Preparative electrochemical reduction of 2-amino-6-chloropurine and synthesis of 6-deoxyacyclovir, a fluorescent substrate of xanthine oxidase and a prodrug of acyclovir. Acta Chem Scand B. 1987 Nov;41(10):701–707. doi: 10.3891/acta.chem.scand.41b-0701. [DOI] [PubMed] [Google Scholar]
  19. Martin D. F., Parks D. J., Mellow S. D., Ferris F. L., Walton R. C., Remaley N. A., Chew E. Y., Ashton P., Davis M. D., Nussenblatt R. B. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol. 1994 Dec;112(12):1531–1539. doi: 10.1001/archopht.1994.01090240037023. [DOI] [PubMed] [Google Scholar]
  20. Neyts J., Andrei G., Snoeck R., Jähne G., Winkler I., Helsberg M., Balzarini J., De Clercq E. The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication. Antimicrob Agents Chemother. 1994 Dec;38(12):2710–2716. doi: 10.1128/aac.38.12.2710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Palestine A. G., Stevens G., Jr, Lane H. C., Masur H., Fujikawa L. S., Nussenblatt R. B., Rook A. H., Manischewitz J., Baird B., Megill M. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. Am J Ophthalmol. 1986 Jan 15;101(1):95–101. doi: 10.1016/0002-9394(86)90470-8. [DOI] [PubMed] [Google Scholar]
  22. Sanborn G. E., Anand R., Torti R. E., Nightingale S. D., Cal S. X., Yates B., Ashton P., Smith T. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol. 1992 Feb;110(2):188–195. doi: 10.1001/archopht.1992.01080140044023. [DOI] [PubMed] [Google Scholar]
  23. Schulman J., Peyman G. A., Horton M. B., Liu J., Fiscella R., Pulido J., Barber J. C., de Miranda P. Intraocular 9-([2-hydroxy-1-(hydroxymethyl) ethoxy] methyl) guanine levels after intravitreal and subconjunctival administration. Ophthalmic Surg. 1986 Jul;17(7):429–432. [PubMed] [Google Scholar]
  24. Shakiba S., Assil K. K., Listhaus A. D., Munguia D., Flores-Aguilar M., Vuong C., Wiley C. A., Tolman R. L., Karkas J. D., Bergeron-Lynn G. Evaluation of retinal toxicity and liposome encapsulation of the anti-CMV drug 2'-nor-cyclic GMP. Invest Ophthalmol Vis Sci. 1993 Sep;34(10):2903–2910. [PubMed] [Google Scholar]
  25. Ussery F. M., 3rd, Gibson S. R., Conklin R. H., Piot D. F., Stool E. W., Conklin A. J. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology. 1988 May;95(5):640–648. doi: 10.1016/s0161-6420(88)33147-7. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES